Novel nasal spray reduces viral replication by up to 96%: according to COVID-19 challenge study

Ena Respiratoryâs preventative nasal spray treatment could reach human trials within four months, following results from an animal study released today which showed the spray reduced COVID-19 replication by up to 96%.